1AI
vs
S
S&P/ASX 300
1AI
Over the past 12 months, 1AI has significantly outperformed S&P/ASX 300, delivering a return of +38% compared to S&P/ASX 300's +2% growth.
Stocks Performance
1AI vs S&P/ASX 300
Performance Gap
1AI vs S&P/ASX 300
Performance By Year
1AI vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Algorae Pharmaceuticals Ltd
Glance View
Algorae Pharmaceuticals Ltd is a small Australian drug-development company that uses artificial intelligence to help find and design new medicines. It does not sell finished drugs today; instead, it works on early-stage pharmaceutical research and builds a pipeline of candidate treatments that may later be licensed or developed further with partners. Its main business is to create value from drug candidates and its AI-driven discovery process, then turn that into income through research collaborations, licensing deals, and other partnership agreements if programs progress. Because drug development takes a long time and carries high failure risk, the company’s customers are usually not patients or pharmacies today, but rather larger pharmaceutical or biotech partners that may fund, license, or advance its work. What makes Algorae different is that it sits at the very early end of the healthcare value chain. Instead of manufacturing medicines at scale, it focuses on discovering and selecting promising drug ideas and trying to move them toward commercial development, which is a common model for small biotech firms that rely on outside capital and partner support while they work through research and clinical testing.
